Sascha Dublin’s main interest is studying the impact of therapeutic interventions, including medications, using real-world observational data. Through this work she aims to provide patients and health care providers with better information about the risks and benefits of different treatment options so they can make more informed decisions. Her work includes studies of medication use in relation to pneumonia risk and dementia risk in older adults. She seeks to improve the methods used to study drug safety in older adults by exploring biases that may arise when observational studies do not take into account coexisting illnesses and functional and cognitive status.
Dr. Dublin’s research also focuses on the outcomes of common interventions in pregnancy, including elective induction of labor (that is, bringing on labor when there is not a medical or obstetrical reason for immediate delivery). Her goal is to take advantage of the rich clinical data that are becoming increasingly available through electronic medical records to develop new knowledge and improve care. Dr. Dublin holds an R01 grant from the National Institute of Child Health and Human Development to study maternal and infant outcomes after elective induction of labor at term gestation. She is also the Group Health site principal investigator for the Medication Exposure in Pregnancy Risk Evaluation Program funded by the Food and Drug Administration (FDA).
Dr. Dublin’s methodological interests include epidemiologic methods, such as case-control studies and techniques to measure and control for potential confounding factors. She has experience with two-phase study designs and has led methods-focused workgroups for the FDA’s Mini-Sentinel Initiative. She is also interested in novel methods to extract information from clinical records, such as natural language processing.
Dr. Dublin collaborates with the Group Health Research Institute (GHRI)’s aging and immunization research teams, and her experience includes work with the Cardiovascular Health Research Unit, a joint division of GHRI and the University of Washington. She previously held a five-year Paul B. Beeson Career Development Award in Aging Research. She is a board-certified general internist who sees patients one day a week in primary care at Group Health.
Hansen C, Andrade SE, Freiman H, Dublin S, Haffenreffer K, Cooper WO, Cheetham TC, Toh S, Li DK, Raebel MA, Kuntz JL, Perrin N, Rosales AG, Carter S, Pawloski PA, Maloney EM, Graham DJ, Sahin L, Scott PE, Yap J, Davis R. Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. Pharmacoepidemiol Drug Saf. 2015 Nov 24. doi: 10.1002/pds.3919. [Epub ahead of print]. PubMed
Floyd JS, Wiggins KL, Christiansen M, Dublin S, Longstreth WT, Smith NL, McKnight B, Heckbert SR, Weiss NS, Psaty BM. Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke. Pharmacoepidemiol Drug Saf. 2015 Nov 8. doi: 10.1002/pds.3914. [Epub ahead of print]. PubMed
Von Korff M, Dublin S, Walker RL, Parchman M, Shortreed SM, Hansen RN, Saunders K. The impact of opioid risk reduction initiatives on high-dose opioid prescribing for chronic opioid therapy patients. J Pain. 2015 Oct 14. pii: S1526-5900(15)00908-6. doi: 10.1016/j.jpain.2015.10.002. [Epub ahead of print]. PubMed
Black MH, Zhou H, Sacks DA, Dublin S, Lawrence JM, Harrison TN, Reynolds K. Prehypertension prior to or during early pregnancy is associated with increased risk for hypertensive disorders in pregnancy and gestational diabetes. J Hypertens. 2015 Sep;33(9):1860-7. doi: 10.1097/HJH.0000000000000646.
Dr. Sascha Dublin describes a Group Health-UW finding that benzodiazepines probably don’t cause dementia. But she cautions that they’re still bad for you.
Read it in Healthy Findings.
March 2, 2015—Group Health study suggests higher risk with acute or chronic use
HealthDay (syndicated), Mar. 3, 2015